Monitor the October 27 KOL event for any new clinical data or updates on the PROACT 1 trial timeline, which could serve as a near-term catalyst. The event is informational and unlikely to move the stock materially unless unexpected data or regulatory commentary emerges.
Price Chart
Executive Summary
ProKidney announced a virtual KOL event on October 27, 2026, featuring Dr. Katherine Tuttle to discuss new insights into rilparencel's mechanism of action from ASN Kidney Week 2026 presentations, along with a corporate update. The event is a routine pipeline-awareness activity with no new clinical data or regulatory milestone disclosed.
Key Facts
- Virtual KOL event scheduled for October 27, 2026, at 10:30 AM ET
- Event will feature nephrology leader Dr. Katherine Tuttle and ProKidney's Head of R&D
- Discussion will cover new insights into rilparencel's mechanism of action from ASN Kidney Week 2026
- Company management will provide a corporate update during the event
- Rilparencel is a first-in-class autologous cell therapy with regenerative medicine advanced therapy designation
- Ongoing Phase 3 REGEN-006 (PROACT 1) study for advanced CKD and type 2 diabetes
- Cash runway expected to support operating plans into mid-2027
Financial Impact
No financial figures disclosed; cash runway guidance into mid-2027 reiterated
Risk Factors
- No new clinical data or regulatory milestone announced; event may be viewed as non-material
- Phase 3 trial results remain the key catalyst; any delay or negative readout would be highly impactful
- Cash runway only into mid-2027, raising potential future financing needs
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3386384 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | Press Release | $1.43 | awaiting T+20 | awaiting T+20 | $1.51 (+5.94%) |
Aug 10, 2026 11w ago | 8-K | $1.61 $1.85 | ▲ +14.91% | ▲ +15.97% | $1.51 (−5.90%) |
Aug 10, 2026 11w ago | Press Release | $1.61 $1.85 | ▲ +14.91% | ▲ +15.97% | $1.51 (−5.90%) |
May 15, 2026 23w ago | 8-K | $1.66 $1.67 | ▲ +0.60% | ▼ −1.52% | $1.51 (−8.73%) |
May 15, 2026 23w ago | Press Release | $1.66 $1.67 | ▲ +0.60% | ▼ −1.52% | $1.51 (−8.73%) |
Apr 17, 2026 27w ago | DEFA14A | $2.10 $1.61 | ▼ −23.33% | ▼ −27.54% | $1.51 (−27.86%) |
Mar 18, 2026 31w ago | Press Release | $1.95 $2.18 | ▲ +11.79% | ▲ +4.17% | $1.51 (−22.31%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers